After Hours Decliner
NEUP Neuphoria Therapeutics15.40-0.12-0.8%
After Hours:5.25-10.15 (-65.9%)
Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder
Globe NewswireMon, 20-Oct 4:15 PM
